HUTCHMED (China) Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HCM research report →
Range $13.6 – $45
Price Chart
About the company
HUTCHMED (China) Limited, a biopharmaceutical company established in 2000 and headquartered in Central, Hong Kong, focuses on the discovery, development, and commercialization of innovative targeted therapies and immunotherapies. The company primarily addresses cancer and immunological disorders, serving a global patient population in addition to Hong Kong. Its operations are structured into two main segments: Oncology/Immunology and Other Ventures.
- CEO
- Chig Fung Cheng
- IPO
- 2016
- Employees
- 1,796
- HQ
- Hong Kong, HK
Get TickerSpark's AI analysis on HCM
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $2.31B
- P/E
- 148.04
- Fwd P/E
- 35.18
- PEG
- -1.53
- P/S
- 4.33
- P/B
- 1.88
- EV/EBITDA
- -115.43
- Div Yield
- 0.00%
- Gross Margin
- 0.20%
- Op Margin
- -6.33%
- Net Margin
- 3.26%
- ROE
- 1.43%
- ROIC
- -2.15%
Latest fiscal year · YoY change
- Revenue
- $549.96M-12.7%
- Gross Profit
- $212.72M-24.7%
- Op Income
- $-54,725,352
- Net Income
- $458.12M+1114.2%
- EPS
- $2.65+1101.8%
- OCF Growth
- -13109.5%
- FCF Growth
- -409.3%
- 52W High
- $16.33
- 52W Low
- $9.77
- 50D MA
- $14.10
- 200D MA
- $13.16
- Beta
- 0.43
- RSI (14)
- 39
- Avg Volume
- 64.98K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
HUTCHMED ended 2025 with strong ex-China FRUZAQLA growth, a cash-rich balance sheet, and an accelerating pipeline led by savolitinib, sovleplenib, and the ATTC platform.· March 5, 2026
- Ex-China FRUZAQLA in-market sales grew 26% year over year to $366 million and now spans more than 38 countries.
- Total oncology revenue was $286 million, including $71 million of R&D-related upfront and milestone revenue; net income was $457 million, mainly from a $416 million SHPL divestment gain.
- China oncology sales improved sharply in the second half, with 21% in-market sales growth versus first-half interim results and 33% second-half growth in ELUNATE.
- R&D spending was $148 million in 2025, and management said the company plans to ramp up toward a longer-term range of $250 million to $300 million as more programs advance.
- 2026 oncology revenue guidance is $330 million to $450 million, with growth expected from China product momentum, new indications, and continued FRUZAQLA geographic expansion.
For 2025, HUTCHMED reported total oncology revenue of $286 million, including $71 million of R&D-related upfront and milestone revenues. Net income was $457 million, driven mainly by a $416 million SHPL divestment gain; excluding that one-time item, management said core operations remained profitable. R&D expenses were $148 million. Commercially, ex-China FRUZAQLA in-market sales grew 26% year over year to $366 million, while China sales rebounded in the second half, with 21% in-market sales growth versus first-half interim results and 33% second-half growth in ELUNATE. Looking to 2026, management guided oncology revenue to $330 million to $450 million, citing continued FRUZAQLA expansion, China growth from new indications, and potential contribution from partnership opportunities and licensing income.
Johnny Cheng framed 2025 as a year of execution on the commercial portfolio and early-stage platform buildout. He emphasized the $1.4 billion cash balance as a strategic advantage that can support ATTC development, possible in-licensing, and M&A, while also keeping the company profitable. His tone was constructive and confident, highlighting multiple upcoming NDA filings, the expansion of hematology products, and a broader second wave of growth beyond the existing oncology base.
Lorenso Chiu highlighted the reported figures: $286 million in total oncology revenue, $71 million of R&D-related upfront and milestone revenue, $457 million of net income, and $148 million of R&D expense for 2025. He said expenses were lower than 2024 because many late-stage trials are nearing completion and multiple NDAs are awaiting approval, while investment is shifting toward early-stage ATTC assets. He also reiterated that cash stands at about $1.4 billion, which positions the company to accelerate ATTC development and consider external opportunities.
Analysts focused on the wide 2026 revenue guide, the timing of SAFFRON, commercial headwinds in the first half, and how investors should think about ATTC. Management said the guidance reflects a second-half recovery, growth from new indications such as RCC for ELUNATE, and continued FRUZAQLA expansion across more markets. On SAFFRON, they repeatedly said the readout is expected in mid-2026, while ATTC data are still early and no definitive timeline was given. On commercialization, management said earlier staffing was overbuilt after the GC setback, but turnover is now much lower and the team has been stabilized heading into 2026.
The call showed multiple sources of potential growth: FRUZAQLA’s ex-China expansion, a China recovery in the second half, and several upcoming regulatory and clinical milestones. Management also sounded optimistic about the ATTC platform now that A251 and 580 are in clinical development and partnership discussions with multinational companies are ongoing.
Several businesses are still facing pressure, including ORPATHYS and SULANDA, which management said were soft due to fierce competition. The U.S. faces Medicare Part D redesign headwinds for FRUZAQLA, and SAFFRON’s readout slipped from the first half to mid-2026. The ATTC platform remains early, with no definitive readout timetable, and the company acknowledged that some growth depends on approvals, label expansions, and partnership execution.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 95.7%
- Shares Outstanding
- 178.14M
- Float Shares
- 170.46M
of shares held by institutions
56 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Schroder Investment Management Group | 1.48M | 0 |
| Allianz Asset Management Gmbh | 674.51K | ▼ 162.96K |
| State Street Corp | 318.20K | ▲ 4.59K |
| Aia Group Ltd | 266.66K | ▼ 24.57K |
| M&G PLC | 237.88K | ▼ 4.91K |
| Jane Street Group, LLC | 235.03K | ▲ 40.56K |
| Amundi | 134.63K | ▼ 69.75K |
| Renaissance Technologies LLC | 116.10K | ▼ 14.10K |
| Xy Capital Ltd | 104.13K | ▲ 55.74K |
| Bnp Paribas Financial Markets | 73.00K | ▼ 31.43K |
| Ubs Group AG | 66.54K | ▲ 22.35K |
| Two Sigma Investments, LP | 63.25K | ▲ 63.25K |
Held by 12 ETFs
Biggest fund positions in HCM by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 20, 26 | Cheng Chig Fung | other | 30,157 |
| May 20, 26 | Cheng Chig Fung | other | 26,307 |
| May 20, 26 | Nixon Charles George Rupert | other | 7,644 |
| May 20, 26 | Nixon Charles George Rupert | other | 7,445 |
| May 20, 26 | Su Wei-guo | other | 132,864 |
| May 20, 26 | Su Wei-guo | other | 75,140 |
| May 20, 26 | Chiu Lorenso | other | 8,863 |
| May 20, 26 | Chiu Lorenso | other | 5,176 |
| May 12, 26 | Mok Tony Shu Kam | other | 0 |
| Dec 11, 19 | Nixon Charles George Rupert | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our HCM coverage
Recent articles, reports, and earnings notes.
No research on HCM yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate HCM report →HUTCHMED Announces China NMPA Approval of SYVIK® (sovleplenib) for the Treatment of Primary Immune Thrombocytopenia and Warm Antibody Autoimmune Hemolytic Anemia
globenewswire.com · Nov 19
HUTCHMED Highlights HMPL-A830 Pre-Clinical Data Presented at the 38th EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics
globenewswire.com · Nov 18
HUTCHMED Announces Expanded Coverage on National Reimbursement Drug List for ELUNATE® and ORPATHYS®
globenewswire.com · Nov 15
HUTCHMED (China) Limited (HCM) Presents at Deutsche Bank Virtual Investor Conference Transcript
seekingalpha.com · Nov 12
Braveheart Bio Reports Third Quarter 2026 Financial Results and Provides Business Update
globenewswire.com · Nov 10
Edgewise Therapeutics Announces Productive End-of-Phase 2 Meeting with FDA for EDG-7500 in HCM; Phase 3 Protocol Features Tolerability-Based Dose Escalation Without Safety Echo Monitoring
prnewswire.com · Nov 5
HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Autoimmune Hemolytic Anemia
globenewswire.com · Nov 4
HUTCHMED Announces Regulatory Filings Accepted for Review for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer in Europe and Japan
globenewswire.com · Nov 1
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.